Dupilumab for the Treatment of Eosinophilic Esophagitis: Real‐Life Long‐Term Effectiveness, Safety and Retreatment After Drug Holiday
Аннотация
ABSTRACT Background Eosinophilic esophagitis (EoE) is a chronic T‐helper Type 2 (Th2)‐mediated inflammatory disorder with sharply increasing incidence and prevalence. While dupilumab is the first biologic approved for EoE, long‐term real‐world data on effectiveness, safety, and treatment discontinuation outcomes remain scarce. Methods We conducted a prospective single‐center observational study of adult patients with EoE treated with dupilumab. Clinical, endoscopic, and histological effectiveness, safety profile, and outcomes following accidental treatment discontinuation were analyzed. Results Ten patients were included with a median follow‐up of 57 months (IQR 44.25–64.75). The median SDI‐PRO score decreased from 1 (IQR 0–3.75) to 0 (IQR 0–0) points at 6 months and remained 0 (IQR 0–0) points at last follow‐up. Endoscopic and histological remission were achieved in most patients after 6 months of therapy (100% and 70%, respectively) and at last follow‐up (100% and 100%, respectively). No serious adverse events were observed. Notably, two patients who accidentally discontinued therapy experienced rapid clinical and endoscopic relapse within a few weeks and regained complete remission within 1 month of retreatment. Conclusions This study provides long‐term real‐world data supporting the sustained effectiveness and favorable safety profile of dupilumab in EoE. The rapid relapse observed after accidental discontinuation, even in patients with deep remission, highlights the importance of identifying predictors of relapse before considering dose de‐escalation strategies.